Key Research Insights on Broadcom, Oracle, and Cisco Systems
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2025
0mins
Should l Buy MRNA?
Source: NASDAQ.COM
Zacks Research Daily Highlights: The article features research reports on 16 major stocks, including Broadcom, Oracle, and Cisco, along with a unique focus on micro-cap stock United-Guardian. The reports are selected from around 70 published by the Zacks analyst team.
Broadcom's Performance: Broadcom has shown strong growth, particularly in AI semiconductors, but faces challenges with contracting gross margins and high debt levels.
Oracle's Growth: Oracle reported a 12% year-over-year revenue increase, driven by cloud services, and expects significant capital expenditures for infrastructure expansion.
Cisco's Business Model Shift: Cisco has transitioned to a subscription-based revenue model, enhancing its portfolio through acquisitions, but is experiencing sluggish sales in its networking segment due to competition and demand issues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 52.845
Low
17.00
Averages
32.47
High
63.00
Current: 52.845
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
S&P 500 Futures Hold Steady in Pre-Market Session; Moderna and SSR Mining Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Moderna Inc. Performance: Moderna Inc. (MRNA) saw an 11.0% increase in pre-market trading.
- SSR Mining Inc. Performance: SSR Mining Inc. (SSRM) experienced a 9.2% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Crude Oil Prices Surge Amid Ongoing Middle East Conflict
- Oil Price Surge: Amid the ongoing U.S.-Israel-Iran conflict, April WTI crude futures rose by 1.05% to $75.34 per barrel, reflecting market concerns over energy supply disruptions.
- Market Response: Despite the tensions in the Middle East, S&P futures increased by 0.13%, Dow futures edged up by 0.03%, and Nasdaq futures rose by 0.22%, indicating a recovery in investor confidence.
- Trump's Statement: President Trump announced that the U.S. will ensure the free flow of energy globally and may deploy the Navy to escort tankers through the Strait of Hormuz, aiming to alleviate concerns over potential supply interruptions.
- Bitcoin Impact: Bitcoin surged nearly 7% in the past 24 hours, boosting stocks like Strategy, Robinhood, and Coinbase in pre-market trading, highlighting the active state of the cryptocurrency market.
See More
Movers: Moderna, CrowdStrike, GitLab, Coinbase, Strategy, Broadcom, and Others
- Stock Market Movement: Stock futures were showing slight increases on Wednesday.
- Investor Sentiment: Investors are assessing the potential for the U.S.-Iran conflict to escalate into a prolonged war.
See More
Moderna Shares Surge as Major Risk is Removed.
- Moderna's Stock Performance: Moderna's stock experienced a rally on Wednesday following positive news regarding a legal settlement.
- Patent Litigation Resolution: The company settled patent litigation with Arbutus Biopharma and Genevant Sciences, which contributed to the stock's increase.
See More
U.S. Stocks Decline Amid Rising Iran Conflict Tensions
- CrowdStrike Earnings Beat: CrowdStrike Holdings Inc. reported fourth-quarter revenue of $1.31 billion, exceeding estimates, with subscription revenue up 23% year-over-year and annual recurring revenue hitting $5.25 billion, highlighting massive growth opportunities from AI adoption, as the stock rose 1.70% to $391.42.
- Mobix Labs Stock Surge: Mobix Labs, Inc. shares skyrocketed 532.77% to $1.12 after securing a production purchase order for high-reliability filtering components essential to the U.S. Navy’s Tomahawk missile program, underscoring rising demand from ongoing missile manufacturing schedules, with the stock gaining an additional 5.36% in after-hours trading.
- Micron Stock Decline: Micron Technology Inc. saw its stock drop 7.99% to $379.68, despite a 52-week high of $455.48, reflecting growing concerns about future performance amid semiconductor industry volatility.
- Target Exceeds Profit Expectations: Target Corporation's stock advanced 6.77% to $120.80, with adjusted earnings of $2.44 per share despite a slight sales dip, driven by growth in food, beauty, and toy categories, while gross margins improved to 26.6% through lower costs and advertising gains.
See More
Moderna Settles Patent Litigation with Arbutus and Genevant
- Settlement Amount Confirmed: Moderna has settled patent litigation with Arbutus Biopharma and Genevant Sciences by agreeing to pay $950 million related to its Spikevax and mRESVIA vaccines, ensuring no future royalties are owed, thereby alleviating financial burdens on the company.
- Cash Flow Outlook Upgraded: With the settlement fee to be incurred in Q3, Moderna now expects cash and cash equivalents to reach between $4.5 billion and $5 billion by year-end, indicating robust financial health and future investment capacity.
- Potential Liability Risks: Despite the settlement, Moderna could still face an additional $1.3 billion in liabilities depending on the outcome of its appeal to the US Federal Circuit, which may impact the company's cash flow and financial planning.
- Vaccine Portfolio Prospects: The settlement provides certainty for Moderna's entire infectious disease portfolio, including future vaccines like mNEXSPIKE and mCOMBRIAX, enhancing the company's competitive edge and innovation capabilities in the vaccine market.
See More
S&P 500 Futures Hold Steady in Pre-Market Session; Moderna and SSR Mining Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Moderna Inc. Performance: Moderna Inc. (MRNA) saw an 11.0% increase in pre-market trading.
- SSR Mining Inc. Performance: SSR Mining Inc. (SSRM) experienced a 9.2% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment among investors for these companies.
See More
Crude Oil Prices Surge Amid Ongoing Middle East Conflict
- Oil Price Surge: Amid the ongoing U.S.-Israel-Iran conflict, April WTI crude futures rose by 1.05% to $75.34 per barrel, reflecting market concerns over energy supply disruptions.
- Market Response: Despite the tensions in the Middle East, S&P futures increased by 0.13%, Dow futures edged up by 0.03%, and Nasdaq futures rose by 0.22%, indicating a recovery in investor confidence.
- Trump's Statement: President Trump announced that the U.S. will ensure the free flow of energy globally and may deploy the Navy to escort tankers through the Strait of Hormuz, aiming to alleviate concerns over potential supply interruptions.
- Bitcoin Impact: Bitcoin surged nearly 7% in the past 24 hours, boosting stocks like Strategy, Robinhood, and Coinbase in pre-market trading, highlighting the active state of the cryptocurrency market.
See More
Movers: Moderna, CrowdStrike, GitLab, Coinbase, Strategy, Broadcom, and Others
- Stock Market Movement: Stock futures were showing slight increases on Wednesday.
- Investor Sentiment: Investors are assessing the potential for the U.S.-Iran conflict to escalate into a prolonged war.
See More
Moderna Shares Surge as Major Risk is Removed.
- Moderna's Stock Performance: Moderna's stock experienced a rally on Wednesday following positive news regarding a legal settlement.
- Patent Litigation Resolution: The company settled patent litigation with Arbutus Biopharma and Genevant Sciences, which contributed to the stock's increase.
See More
U.S. Stocks Decline Amid Rising Iran Conflict Tensions
- CrowdStrike Earnings Beat: CrowdStrike Holdings Inc. reported fourth-quarter revenue of $1.31 billion, exceeding estimates, with subscription revenue up 23% year-over-year and annual recurring revenue hitting $5.25 billion, highlighting massive growth opportunities from AI adoption, as the stock rose 1.70% to $391.42.
- Mobix Labs Stock Surge: Mobix Labs, Inc. shares skyrocketed 532.77% to $1.12 after securing a production purchase order for high-reliability filtering components essential to the U.S. Navy’s Tomahawk missile program, underscoring rising demand from ongoing missile manufacturing schedules, with the stock gaining an additional 5.36% in after-hours trading.
- Micron Stock Decline: Micron Technology Inc. saw its stock drop 7.99% to $379.68, despite a 52-week high of $455.48, reflecting growing concerns about future performance amid semiconductor industry volatility.
- Target Exceeds Profit Expectations: Target Corporation's stock advanced 6.77% to $120.80, with adjusted earnings of $2.44 per share despite a slight sales dip, driven by growth in food, beauty, and toy categories, while gross margins improved to 26.6% through lower costs and advertising gains.
See More
Moderna Settles Patent Litigation with Arbutus and Genevant
- Settlement Amount Confirmed: Moderna has settled patent litigation with Arbutus Biopharma and Genevant Sciences by agreeing to pay $950 million related to its Spikevax and mRESVIA vaccines, ensuring no future royalties are owed, thereby alleviating financial burdens on the company.
- Cash Flow Outlook Upgraded: With the settlement fee to be incurred in Q3, Moderna now expects cash and cash equivalents to reach between $4.5 billion and $5 billion by year-end, indicating robust financial health and future investment capacity.
- Potential Liability Risks: Despite the settlement, Moderna could still face an additional $1.3 billion in liabilities depending on the outcome of its appeal to the US Federal Circuit, which may impact the company's cash flow and financial planning.
- Vaccine Portfolio Prospects: The settlement provides certainty for Moderna's entire infectious disease portfolio, including future vaccines like mNEXSPIKE and mCOMBRIAX, enhancing the company's competitive edge and innovation capabilities in the vaccine market.
See More
